 Protalix BioTherapeutics Inc NYSE: PLX and its collaborating partner Chiesi Farmaceutici S.p.A. announced positive topline results from the BRIGHT Phase 3 trial evaluating pegunigalsidase alfa PRX102 for the potential treatment of Fabry disease. 